| HOME >> BIOLOGY >> TECHNOLOGY |
e responsibility to reduce our environmental footprint."
This latest investment complements two additional expansion projects at the Arklow site: the building of a $2.25-million, 15 kg capacity pilot-scale filter dryer designed to double the facility's current capacity for small-scale (10 kg-150 kg) manufacturing of APIs, due for commission in third-quarter 2009; and a $1.8-million expansion of the site's cGMP warehouse capacity, also scheduled for completion in 2009.
"Enhancements to our Ireland site help us strengthen our position as the leading pipeline partner for the pharmaceutical industry, offering complete support for the development, manufacturing and testing of APIs - from preclinical to commercialization stages," concluded Harris.
The 64,000 cubic meter Arklow complex is cGMP, FDA and IMB inspected and fully validated. It supports customers with expertise in new process evaluation, process development validation and technology transfer. The site's special process technologies include carbon coupling reactions, polyamino acids, Suzuki coupling reagents, distillations, salt formations, Grignard chemistry and powder handling, and it is one of the industry's few sites to offer large-scale simulated moving bed (SMB) chromatography for chiral separations.
About SAFC: SAFC(R) is the custom manufacturing and services group
within Sigma-Aldrich that focuses on high-purity inorganics for high
technology applications, cell culture products and services for
biopharmaceutical manufacturing, biochemical production and the
manufacturing of complex, multi-step organic synthesis of APIs and key
intermediates. SAFC has manufacturing facilities around the world dedicated
to providing manufacturing services for companies requiring a reliable
partner to produce their custom manufactured materials. SAFC has four focus
areas - SAFC Pharma(TM), SAFC Supply Solutions(R), SAFC Biosciences(TM),
and SAFC Hitech(TM) - and had annual sales of nearly $600 mi
'/>"/>
| SOURCE Sigma-Aldrich Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
2. Novagali Pharma Completes a EUR15 Million Fund Raising
3. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908
4. Napo Pharmaceuticals Will Provide Pediatric Formulation of Crofelemer at Cost to Developing Nations to Help Treat Life-Threatening Diarrhoel Diseases (Subject to FDA Approval)
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
7. New USP 797 Regulations May Create New Hazards for Compounding Pharmacy Directors
8. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
9. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
10. AIT Laboratories Expands Pharma Services
11. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |